Survival Analysis Based on Clinicopathological Data from a Single Institution: Chemotherapy Intensity Would Be Enhanced in Patients with Positive Hormone Receptors and Positive HER2 in China Who Cannot Afford the Target Therapy

Table 3

Survival analysis.

Parameters	Luminal A (𝑛=66)	Luminal B (𝑛=55)	HER2+ (𝑛=26)	TNBC (𝑛=52)	Statistics (𝐹 or 𝑋^2)	𝑃
Overall survival	66 (100%)	47 (85.5%)	22 (84.6%)	45 (86.5%)	10.432	0.015
Event	0 (0%)	8 (14.5%)	4 (15.4%)	7 (13.5%)
Deaths	0	3	2	3
Death of BC	0	2	2	2
Death of NBC	0	1	0	0
Lost to followup	0	5	2	4
Median survival time	66	60	60	66	8.749	0.033
Disease-free survival	66 (100%)	46 (83.6%)	21 (80.8%)	44 (84.6%)	12.477	0.006
Event	0 (0%)	9 (16.4%)	5 (19.2%)	8 (15.4%)
Tumor progression	0	3	3	4
Local recurrence	0	1	0	1
Contralateral BC	0	0	1	0
Bone	0	0	2	0
Hepatic	0	1	0	0
Multiorgan	0	1	0	3
Death of NBC	0	1	0	0
Lost to followup	0	5	2	4
Disease-free survival	66	60	60	66	10.850	0.013
Follow-up time					2.206	0.089
Median	33.5	30.0	39.0	33.0
Range	25~66	17~65	13~65	18~66